NEW YORK, July 23-Massachusetts General Hospital and NeoGenesis Pharmaceuticals announced today a four-year proteomics-based drug discovery collaboration.
Through the partnership, MGH molecular biologist Brian Seed will provide the company with proteins believed to play a role in disease. NeoGenesis will use its compound libraries and ligand screening system to identify compounds that interact with these proteins. MGH will characterize the compounds in assays and animal models, and NeoGenesis will take over clinical development.
The partners will look for drugs to target cancer and inflammatory disease. Financial details were not disclosed.
Seed studies gene expression in angiogenesis and signal transduction in the immune response, and has a proteomics facility in Cambridge, Mass that can produce and characterize disease-associated proteins.